Skip to content

Emotion Regulation Dysfunctions in NSSI Adolescents in Naturalistic Contexts

Altered Neural Activation Patterns During Emotion Regulation in Adolescents With Nonsuicidal Self-Injury Under Naturalistic Immersive Emotional Engagement

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05907421
Enrollment
80
Registered
2023-06-18
Start date
2023-12-06
Completion date
2027-06-30
Last updated
2024-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emotion Regulation, Nonsuicidal Self Injury

Brief summary

Nonsuicidal self-injury (NSSI) is defined as direct, deliberate bodily harm without suicidal intention. Recent studies indicate that prevalence rates are increasing worldwide, in particular under adolescents, indicating a growing public health issue. An impaired ability to regulate negative emotion has been suggested to play a potential role in NSSI behavior. Some recent interventions aim at improving dysfunctional emotion regulation via 'acceptance'. Acceptance represents an objective, nonreactive, nonjudgmental, and calming emotion regulation strategy, partly based on the philosophy of dialectical behavior therapy (DBT) that has been widely used in the clinical treatment of NSSI behaviors. The aim of the present functional magnetic resonance imaging (fMRI) study is to examine whether adolescents with NSSI can implement the acceptance strategy in naturalistic emotional contexts (immersive video clips) and whether they differ from healthy controls in terms of behavioral and neural effects. To this end, the investigators recruit one group of NSSI adolescents (n=40) and one healthy control group (n=40), to compare the subjective emotional experience as well as underlying neural activity as measured by blood oxygenation level-dependent (BOLD) fMRI. The investigators hypothesize that compared to HC, NSSI adolescents will experience stronger negative emotions and show dysregulated neural recruitment of brain systems engaged in emotional reactivity and regulations (e.g. limbic regions, default mode network, and frontal regions).

Interventions

BEHAVIORALAcceptance mindset

Brief training of acceptance versus emotional reactivity as emotion regulation strategy.

Sponsors

University of Electronic Science and Technology of China
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
15 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* 15-18 years * right-handed * normal or corrected normal visual acuity * meet the proposed DSM-5 frequency criteria (e.g., ≥5 days of NSSI behaviors in the past year)

Exclusion criteria

* diagnosis of borderline personality disorder, major depressive disorder, other psychiatric disorders, etc. * high suicidal risk * recent use of medications that can affect neural activity * have received or are receiving Dialectical Behavior Therapy (DBT) other treatment for emotional problems within the past 6 months * have a contraindication to MRI scanning (e.g., metal implants, claustrophobia or other conditions that make them inappropriate for MRI scanning)

Design outcomes

Primary

MeasureTime frameDescription
Negative subjective emotional experience as indexed by self-reportAbout 30 minutesSubjects will rate their negative affect on a scale ranging from 1-9 in response to neutral and negative emotional stimuli during normal experience or acceptance. Alterations in the patients will be determined by using ANOVA models with the group (NSSI vs. HC) as a between-subject factor and emotion regulation condition as a within-subject factor.
Neural activity as indexed by BOLD fMRIAbout 30 minutesBrain activity will be monitored by task-based fMRI. Alterations in the patients will be determined by the experimental groups (NSSI vs. HC) with respect to the emotion regulation conditions.

Countries

China

Contacts

Primary ContactBenjamin Becker
ben_becker@gmx.de+86.028-61830867

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026